TITLE

Alternating recombinant and natural alpha-interferon helps to prevent clinical resistance to interferon in cutaneous T-cell lymphoma treatment

AUTHOR(S)
Altomare, Gianfranco; Capella, Giovanni Luigi; Frigerio, Elena
PUB. DATE
May 1998
SOURCE
Acta Dermato-Venereologica;5/1/1998, Vol. 78 Issue 2, p159
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents a case report regarding the administration of recombinant alpha interferon for the treatment of cutaneous T-cell lymphoma. Influence of antibodies on alpha interferon efficacy; Synthesis of biologically active alpha interferon-neutralizing endogenous antibodies; Applicability of interferons in treating lymphoproliferate diseases.
ACCESSION #
4318165

 

Related Articles

  • I Tositumomab: A Viewpoint by Wolfgang Kern. Kern, W. // BioDrugs;2000, Vol. 14 Issue 3, p203 

    Focuses on the improvements made in understanding the pathogenetic basis of various non-Hodgkin's lymphomas. Comparison of the efficacy of different treatment approaches in specific types of lymphomas; Increase in the dose intensity of radiochemotherapy; Introduction of biologically-based...

  • Acute Non--Lymphoblastic Leukemia After Treatment of Nodular Lymphoma with Human Leukocyte Interferon. Warrell Jr., Raymond P.; Krown, Susan E.; Koziner, Benjamin; Andreeff, Michael; Kempin, Sanford J. // Annals of Internal Medicine;Apr83, Vol. 98 Issue 4, p482 

    Presents a case study of a patient with acute non-lymphoblastic leukemia after the treatment of nodular lymphoma with human leukocyte interferon. Medical history of the patient; Results of laboratory examinations; Discussion of the condition.

  • Traitement de maintenance des lymphomes malins non hodgkiniens. Pascal, L.; Terriou, L.; Morschhauser, F. // Oncologie;Sep2011, Vol. 13 Issue 9, p543 

    Maintenance treatment aims to sustain the response of induction chemotherapy, reduce the relapse rate, and provide a longer progression-free survival and time to the next course of chemotherapy. It must have an acceptable toxicity profile in order to obtain the trust of both patient and...

  • Roferon-A.  // Royal Society of Medicine: Medicines;2002, p481 

    The article presents information on roferon-A, a proprietary, prescription-only preparation of interferon. The drug can be used as an anticancer drug in the treatment of hairy cell leukemia, myelogenous leukemia, certain renal cell lymphoma, follicular non-Hodgkin's lymphoma, as an adjunct to...

  • Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. Herold, Michael; Scholz, Christian; Rothmann, Frank; Hirt, Carsten; Lakner, Volker; Naumann, Ralph // Journal of Cancer Research & Clinical Oncology;Sep2015, Vol. 141 Issue 9, p1689 

    Purpose: The randomised, controlled OSHO#39 study showed promising results using first-line mitoxantrone, chlorambucil and prednisolone (MCP) chemotherapy plus rituximab in patients with advanced symptomatic follicular lymphoma (FL) in need of therapy. The aim of this long-term follow-up was to...

  • Transgene presents positive phase I/II data for adeno-interferon gamma product in cutaneous lymphoma.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p24 

    Reports on Transgene's announcement of positive results from its phase I/II clinical trial of its immunotherapy product candidate ad-IFN gamma in patients with primary cutaneous lymphoma. Presentation of study data at the cancer clinical trials session of the 6th Annual Meeting of the American...

  • Progress in Radioimmunotherapy. Bast, Robert C. // New England Journal of Medicine;10/21/93, Vol. 329 Issue 17, p1266 

    Editorial. Discusses the use of monoclonal techniques in clinical oncology. Non-Hodgkin's lymphoma as an appealing target for monoclonal serologic therapy in vivo; Article by Press, et al, in the October 21, 1993 issue of the `New England Journal of Medicine' dealing with the treatment of...

  • Clinical Trials Explore New. Guttman Strategies for Treatment of CTCL, Cheryl // Dermatology Times;Jul98, Vol. 19 Issue 7, p32 

    Presents several therapeutic approaches for the treatment of cutaneous T-cell lymphoma. Vaccination method to kill T-cells which causes the disease; Treatment with cytokine therapy to restore immune function; Topical application of retinoids.

  • Gastric lymphomas: Before and after. Schmutz, Donald A.; R.M.D. // Cortlandt Forum;6/25/95, Vol. 8 Issue 6, p94 

    Inquires about the preoperative treatment required for an extensive superficial lymphoma that requires total gastrectomy. Increase in frequency of gastric lymphoma; Chemotherapy or radiation as not helpful preoperative treatment; Reference reading.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics